cost-effectiveness Archives -

NICE has rejected regular NHS funding for Pfizer’s Vyndaqel (tafamidis) for a rare heart condition, although it has

NICE says ‘no’ to Pfizer’s Vyndaqel for rare heart condition

https://pharmaphorum.com/news/nice-says-no-to-pfizers-vyndaqel-for-rare-heart-condition/

Market Access/ News/ News

NICE unveils five year plan promising faster access to medicines

Richard Staines cost-effectiveness, market access, NICE, pricing 0 Comment

NICE has included proposals to speed up evaluations and focus on new technology such as digital health in

NICE unveils five year plan promising faster access to medicines

https://pharmaphorum.com/news/nice-unveils-five-year-plan-promising-faster-access-to-medicines/

Market Access/ News/ News

BMS’ MS pill gets funding in Scotland after rejection in England by NICE

Richard Staines cost-effectiveness, market access, multiple sclerosis, neurology, SMC 0 Comment

Scotland’s drugs cost-effectiveness body has recommended Bristol-Myers Squibb’s Zeposia multiple sclerosis pill, setting a potential north-south access divide

BMS’ MS pill gets funding in Scotland after rejection in England by NICE

https://pharmaphorum.com/news/bms-ms-pill-gets-funding-in-scotland-after-rejection-in-england-by-nice/

Market Access/ News/ News

NICE rejects BMS’ Zeposia MS pill in provisional guidance

Richard Staines Bristol-Myers Squibb, cost-effectiveness, market access, multiple sclerosis, Roche, Zeposia 0 Comment

NICE has said that the NHS should not fund Bristol-Myers Squibb’s multiple sclerosis pill Zeposia (ozanimod) for relapsing

NICE rejects BMS’ Zeposia MS pill in provisional guidance

https://pharmaphorum.com/market-access-2/nice-rejects-bms-zeposia-ms-pill-in-provisional-guidance/

Market Access/ News/ News

After two decades, NICE begins consultation on drug assessment methods

Richard Staines cancer, cost-effectiveness, market access, NICE, Rare diseases 0 Comment

The UK’s drug cost-effectiveness body NICE has launched a public consultation, presenting the case for change about how

After two decades, NICE begins consultation on drug assessment methods

https://pharmaphorum.com/news/nice-begins-consultation-on-cost-effectiveness-methods/

Market Access/ News/ News

NICE rejects Sanofi’s Cablivi for rare blood disorder TTP

Richard Staines cost-effectiveness, market access, NICE, Sanofi 0 Comment

NICE has rejected Sanofi’s Cablivi (caplacizumab) for the rare blood disorder thrombotic thrombocytic purpura (TTP) in first draft guidance. The cost-effectiveness body said

NICE rejects Sanofi’s Cablivi for rare blood disorder TTP

https://pharmaphorum.com/news/nice-rejects-sanofis-cablivi-for-rare-blood-disorder-ttp/

Market Access/ News/ News

Study sets benchmark for cost of repurposed coronavirus drugs

Phil Taylor coronavirus, cost-effectiveness, Gilead, remdesivir 0 Comment

Scientists have warned that the main drugs being repurposed for COVID-19 could end up being too expensive for

Study sets benchmark for cost of repurposed coronavirus drugs

https://pharmaphorum.com/news/study-sets-benchmark-for-cost-of-repurposed-coronavirus-drugs/

Market Access/ News/ News/ Oncology

NICE backs NHS funding for Roche’s Kadcyla in early breast cancer use

Richard Staines breast cancer, cancer, cost-effectiveness, Kadcyla, market access, NICE, Roche 0 Comment

NICE has published final draft guidance recommending regular NHS funding for Roche’s Kadcyla (trastuzumab emtansine) in its newer use, for certain people

NICE backs NHS funding for Roche’s Kadcyla in early breast cancer use

https://pharmaphorum.com/market-access-2/nice-backs-nhs-funding-for-roches-kadcyla-in-early-breast-cancer-use/

News/ News/ Oncology/ Top stories

NICE rejects Roche’s Polivy combination in advanced lymphoma

Richard Staines cost-effectiveness, diffuse B-Cell lymphoma, DLBCL, Gilead, lymphoma, NICE, Novartis, Roche 0 Comment

England’s NHS should not fund Roche’s Polivy (polatuzumab vedotin) in combination with rituximab and bendamustine for adults with

NICE rejects Roche’s Polivy combination in advanced lymphoma

https://pharmaphorum.com/news/nice-rejects-roches-polivy/

Trending

cost-effectiveness

Login